Dachaigh › Luchd-obrach › Ascendis Pharma, Inc.
Ascendis Pharma, Inc.: Tuarastalan H-1B agus taic bhìosa
Chuir Ascendis Pharma, Inc. 8 iarrtasan cumha-obrach a-steach airson bhìosaichean H-1B agus bhìosaichean co-cheangailte ann am bliadhnaichean ionmhais 2023–2026; le teisteanas: 8. Tuarastal meadhanach a chaidh a thabhann: $218,160.
A bheil Ascendis Pharma, Inc. a’ toirt taic do bhìosaichean H-1B?
Chuir Ascendis Pharma, Inc. 8 iarrtasan cumha-obrach a-steach ann am bliadhnaichean ionmhais 2023–2026, an tè as ùire air a chur a-steach air 19 Dùbh 2025. Is e LCA a’ chiad cheum ann an iarrtas H-1B, mar sin tha an neach-fastaidh air taic a thoirt do luchd-obrach H-1B no air ullachadh airson sin a dhèanamh; cha gharantaich e taic airson dreuchd shònraichte sam bith. Thoir sùil air liostaichean obrach an neach-fastaidh fhèin.
Iarrtasan cairt uaine (PERM) aig Ascendis Pharma, Inc.: 5 →
Tuarastalan a rèir tiotal obrach
| Tiotal dreuchd | LCAs | Tuarastal meadhanach |
|---|---|---|
| Associate Director, Medical Safety Science | 2 | $225,000 |
| Director, Global PV Operations | 1 | $255,000 |
| IT Business Analyst | 1 | $150,000 |
| Scientist, Formulation Development | 1 | $135,000 |
| Head, Global PV Operations | 1 | $275,600 |
| Associate Director, Global PV Operations | 1 | $216,320 |
| Sr. Specialist, IT Business Analysis | 1 | $175,141 |
Iarrtasan a rèir bliadhna ionmhais
| Bliadhna mhaoine | LCAs | Tuarastal meadhanach |
|---|---|---|
| FY2023 | 6 | $225,000 |
| FY2024 | 1 | $216,320 |
| FY2026 | 1 | $175,141 |
Ìrean tuarastail làithreach
Suidhichidh Roinn an Obrach ceithir ìrean tuarastail làithreach airson gach dreuchd agus sgìre, bho Ìre I (inntrigeadh) gu Ìre IV (gu tur comasach). Taghaidh an neach-fastaidh an ìre a fhreagras ri riatanasan na h-obrach.
Far a bheil na h-obraichean
Dreuchdan
- Medical Scientists, Except Epidemiologists4
- Computer Systems Analysts2
- Regulatory Affairs Managers1
- Regulatory Affairs Specialists1
Iarrtasan as ùire
| Tiotal dreuchd | Tuarastal bunasach | Àite | Air a chur a-steach | Ceann-latha tòiseachaidh | Inbhe |
|---|---|---|---|---|---|
| Sr. Specialist, IT Business Analysis | $175,141 Ìre III | Palo Alto, CA | 19 Dùbh 2025 | 23 Faoi 2026 | Dearbhaichte |
| Associate Director, Global PV Operations | $216,320 Ìre IV | Palo Alto, CA | 12 Iuch 2024 | 29 Samh 2024 | Dearbhaichte |
| Head, Global PV Operations | $275,600 Ìre IV | Palo Alto, CA | 18 Lùna 2023 | 15 Dùbh 2023 | Dearbhaichte |
| Associate Director, Medical Safety Science | $220,000 Ìre IV | Palo Alto, CA | 17 Cèit 2023 | 12 Ògmh 2023 | Dearbhaichte |
| Scientist, Formulation Development | $135,000 Ìre II | Redwood City, CA | 26 Gibl 2023 | 1 Dàmh 2023 | Dearbhaichte |
| Associate Director, Medical Safety Science | $230,000 Ìre IV | Dublin, CA | 16 Gearr 2023 | 20 Màrt 2023 | Dearbhaichte |
| Director, Global PV Operations | $255,000 Ìre IV | Benicia, CA | 14 Gearr 2023 | 21 Gearr 2023 | Dearbhaichte |
| IT Business Analyst | $150,000 Ìre III | Palo Alto, CA | 20 Faoi 2023 | 23 Faoi 2023 | Dearbhaichte |
Is e na tuarastalan an ìre as ìsle den tuarastal a chaidh a thabhann air gach iarrtas, air an tionndadh gu suim bhliadhnail; cleachdaidh na staitistigean iarrtasan làn-aimsire le teisteanas a-mhàin. Chan eil LCA na aontachadh bhìosa agus faodaidh aon LCA còmhdach a dhèanamh air iomadh dreuchd. Stòr: Roinn an Obrach na SA, Dàta Foillseachaidh OFLC LCA, bliadhnaichean ionmhais 2023–2026 (co-dhùnadh as ùire 30 Ògmh 2026).